SCHEMBL21296875

SCHEMBL21296875

O=C(O)c1nn[nH]c1Sc1ccccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.46
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
ALPL P05186 1/20 0.38
HAO1 Q9UJM8 1/20 0.38
LDHA P00338 4/20 0.38
LDHB P07195 3/20 0.38
NOTUM Q6P988 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CLK1 P49759 1/20 0.35
CDK9 P50750 1/20 0.35
CDK5 Q00535 1/20 0.35
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799229 1.00 PKM (0.46) PKMKMT2AMEN1HPGDMAPT
SCHEMBL21296937 0.82 HAO1 (0.38) MAPTHAO1NOTUMALDH1A1
SCHEMBL21296901 0.82 HAO1 (0.38) MAPTHAO1LDHANOTUMALDH1A1
SCHEMBL29799106 0.82 HAO1 (0.38) MAPTHAO1LDHANOTUMALDH1A1
SCHEMBL21296944 0.80 MAPT (0.56) KMT2AMEN1HPGDMAPTLMNA
SCHEMBL29799115 0.80 MAPT (0.56) KMT2AMEN1HPGDMAPTLMNA
SCHEMBL21312823 0.80 ALDH1A1 (0.37) PKMKMT2AMEN1HPGDMAPT
SCHEMBL29799188 0.79 HAO1 (0.42) KMT2AMEN1MAPTALPLHAO1
SCHEMBL21296904 0.79 HAO1 (0.42) KMT2AMEN1MAPTALPLHAO1
SCHEMBL21312713 0.79 ALPL (0.42) PKMALPLHAO1PRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX PKM 1364/4885KMT2A 3943/4885MEN1 3426/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX PKM 1364/4885KMT2A 3943/4885MEN1 3426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.